Investigation Report on China’s Telmisartan Market, 2018-2022 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 20, 2018--The “Investigation Report on China’s Telmisartan Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
By the end of 2017, there were about 330 million hypertensive patients in China, in another word, one in every three adults in China had hypertension. The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017
Angiotensin II receptor antagonists (angiotensin receptor blockers, ARBs) are antihypertensive drugs that has been growing rapidly since it emerged in the 1990s. As an important ARB administered orally once a day to treat essential hypertension.
Telmisartan was discovered by Boehringer Ingelheim and first launched in the U.S. as Micardis in 1999. In the same year, in Germany, it was launched by Boehringer Ingelheim and Glaxo Wellcome in the trades name of Micardis and Pritor respectively. Then it was marketed in several countries. The patent for Telmisartan expired in 2014.
At the end of 2000, Boehringer Ingelheim introduced the active pharmaceutical ingredient and preparations of Telmisartan to China. Telmisartan had developed fast since it entered in China. The sales value kept increasing before 2014 when it began to decrease, reaching about CNY 165 million in 2017.
At present, China’s Telmisartan market is dominated by Boehringer Ingelheim, China Resources Double-Crane Pharmaceutical Co., Ltd., Yichang HEC Changjiang Pharmaceutical Co., Ltd., and Jiangsu Wanbang Biopharmaceuticals Co., Ltd. Boehringer Ingelheim has the largest market share. In 2017, its market share by sales value was about 72.4% but showed a downward trend.
It is expected that with the increasing number of hypertensive patients, China’s Telmisartan market will still have some growth potential.
Companies FeaturedBoehringer Ingelheim (Micardis) China Resources Double-Crane Pharmaceutical Co. Ltd. (Suhe) Jiangsu Wanbang Biopharmaceuticals Co. Ltd. (Bangtan) Suzhou Dawnrays Pharmaceutical Co. Ltd. (Anneiqiang) Yichang HEC Changjiang Pharmaceutical Co. Ltd. (Oumeining)
Key Topics Covered
1 Relevant Concepts of Telmisartan
2 Sales of Telmisartan in China, 2013-2017
3 Analysis of Major Telmisartan Manufacturers in China, 2013-2017
4 Prices of Telmisartan in China, 2017-2018
5 Prospect of China’s Telmisartan Market, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/qhfhjw/investigation?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005357/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/20/2018 07:26 AM/DISC: 12/20/2018 07:27 AM